Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1Available 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Diseases 2Lung Non-Squamous Non-Small Cell Carcinoma 1Lung Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 1270Specimen Handling 921Magnetic Resonance Spectroscopy 832Carboplatin 829Cyclophosphamide 802Cisplatin 726Nivolumab 682Paclitaxel 639Radiotherapy 613Gemcitabine 578Biopsy 556Bevacizumab 477Dexamethasone 445fludarabine 405Docetaxel 382venetoclax 372Oxaliplatin 365Capecitabine 360Fluorouracil 358atezolizumab 345durvalumab 338Rituximab 336Drug Therapy 330Doxorubicin 319Radiosurgery 316Blood Specimen Collection 313Pemetrexed 308Standard of Care 306Ipilimumab 305Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
zipalertinib × 1 year × Clear all
NCT07601399 2026-05-22

An EAP Treatment Protocol of Zipalertinib

Taiho Oncology, Inc.

Available
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07128199 2026-05-05

REZILIENT4

Taiho Oncology, Inc.

Phase 3 Active not recruiting
360 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05967689 2026-04-03

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting
220 enrolled

Carcinoma, Lung Diseases

NCT05973773 2026-03-10

REZILIENT3

Taiho Oncology, Inc.

Phase 3 Active not recruiting
285 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT07229339 2026-02-05

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Not yet recruiting
16 enrolled

Lung Non-Squamous Non-Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡